Replies to post #154910 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

We need to separate completely securing a patent and regulatory approval. The latter doesn't require a patent.

The examples may well hold true, at least that is certainly the intention, but they are not required to reflect a tried and tested scenario. If such an example or one very similar to it is later established, the idea is that the patent teaches that kind of use and thus makes it easier to enforce the patent in an infringement situation.

So definitely I think there is course to be encouraged by the patent and examples, but we should not expect the example to be some kind of true life insight into the progress of patients in the current trial.

[ohsaycanyousee82]

This is from an old patent related post. You can see the theoretical uses listed for the drug:

Data listed under the description tab and comes from the anti-seizure patent: (EN) A 19-144, A2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITOR COMPOSITIONS AND METHOD FOR ANTI-SEIZURE THERAPY

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016064711&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription


Example 1

Seizure Prophylaxis: A19-144

A 13 year old male is experiencing 4 to 7 seizures per day with a baseline of 6.6 seizures per day. A19-144 is administered daily at 2.0 mg for 5 days. Seizures reduce to 2.2 per day for 8 weeks post dosing.

Example 2

Seizure Prophylaxis: A19-144 and Donepezil

The 13 year old male of example 1 is experiencing seizures at 2.2 per day at 6 months post dosing as stated in Example 1 . The subject is administered low dose donepezil (4mg daily) for 5 days cotimely with continued A19-144 administration daily at 2.0 mg for 5 days. No seizures are detected at 6 months post dosing. Cognitive testing detects no diminution of memory as compared with the subject prior to donepezil administration.

Example 3

Seizure Prophylaxis: A19-144

A 57 year old female is experiencing 6 to 8 seizures per day with a baseline of 6.6 seizures per day. A19-144 is administered daily at 2.0 mg for 5 days. Seizures reduce to 1 .2 per day for 8 weeks post dosing.

Example 4

Seizure Prophylaxis: A19-144 and Eslicarbazepine acetate

The 57 year old female of Example 3 is experiencing an average of 1 .2 seizures per day at 6 months post dosing as stated in Example 3. The subject is administered low dose Eslicarbazepine acetate at 600mg/day; for 5 days cotimely with continued A19-144 administration daily at 2.0 mg for 5 days. No seizures are detected at 6 months post dosing. Cognitive testing detects no diminution of memory as compared with the subject prior to Eslicarbazepine acetate administration.

Example 5

Seizure Prophylaxis: A19-144 and Lacosamide

A 10 year old female is experiencing seizures 3.2 per day. The subject is administered lacosamide at 60mg two times per day for 5 days and cotimely

administration of A19-144 daily at 2.0 mg for 5 days. No seizures are detected at 6 months post dosing.

Example 6

Seizure Prophylaxis: A19-144 and Levetiracetam

The 9 year old female is experiencing an average of 3.3 seizures per day. The subject is administered Levetiracetam at 400mg two times per day for 5 days and cotimely administration of 3.0 mg of A19-144 daily for 5 days. No seizures are detected at 6 months post dosing. Cognitive testing detects no diminution of memory as compared with the subject prior to Levetiracetam administration.

The results of Examples 1 through 6 above are similarly effective when A2-73 is substituted for A19-144.